1:00 PM
Dec 08, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Active, Teva's laquinimod misses in Phase II for PPMS

Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg oral laquinimod (SAIK-MS) missed the primary endpoint of reducing brain atrophy on MRI as measured by percent brain volume change from baseline to week 48 compared to placebo in the double-blind, international Phase II ARPEGGIO trial to treat primary progressive multiple sclerosis (PPMS)....

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >